Benesch Names Kevin Humphries and Alan Schabes to Executive Committee

Benesch is pleased to announce the election of partners Kevin W. Humphries and Alan E. Schabes to the firm’s Executive Committee, effective July 1, 2025. They will each serve a three-year term as part of the nine-member board responsible for stewarding the firm and guiding its strategic direction. Kevin and Alan join four returning Executive Committee Members, along with Managing Partner Gregg Eisenberg, Administrative Partner Jeff Wild and Executive Chairman Ira Kaplan.

“Kevin and Alan are trusted partners and respected leaders with a deep commitment to the firm’s continued success,” said Managing Partner Gregg Eisenberg. “Their combined experience and perspectives make them well-suited additions to the Executive Committee, and I am confident they will lead with integrity and thoughtfulness.”

Kevin W. Humphries

Kevin is co-chair of the firm’s Corporate Practice Group, advising public and private companies on mergers and acquisitions, divestitures, strategic investments and general corporate matters. He brings deep transactional experience across industries including software, healthcare, consumer retail and manufacturing. Kevin also counsels institutional investors on fund investments and co-investments, drawing on his prior role as lead counsel to STRS Ohio’s Alternative Investments division, where he helped oversee more than $3.5 billion in capital deployment.

Alan E. Schabes

Alan is a partner in the firm’s Healthcare Practice Group with a nationally recognized practice spanning health care transactions, regulatory counsel and government investigations. He advises private equity and venture firms, hospitals, post-acute providers and management service organizations across the care continuum. Alan brings deep experience in health law compliance, fraud and abuse matters, whistleblower defense and HIPAA-related issues. A Fellow of the American Health Lawyers Association, he is a prolific speaker, author and leader in major industry associations shaping the future of healthcare law.

The membership of the Executive Committee was approved by a vote of the firm’s equity partnership last month.